Cancer Therapy-Induced Oral Mucositis: Current Challenges and the Path toward Precision Prevention and Personalized Management
Oral mucositis (OM) is a common and clinically significant complication of chemotherapy, head and neck radiotherapy, and hematopoietic stem cell transplantation. Current OM research is limited by patient heterogeneity, inconsistent outcome measures, simplified preclinical models, and variable levels of evidence across interventions. This review summarizes these limitations and distinguishes clinically established approaches from emerging and exploratory strategies. Future research should integrate standardized clinical assessment, patient-reported outcomes, multi-omics, salivary biomarkers, imaging and dosimetric data, and externally validated artificial intelligence models. Human-relevant models, including organoids and oral mucositis-on-a-chip platforms, may help bridge the translational gap. Ultimately, risk-adapted prevention and management should be tested in prospective multicenter trials to determine whether they reduce OM burden while supporting completion of planned cancer therapy.